Open AccessS0752 Infliximab Level <3 µg/ml Predicts Immune-Mediated Loss of Response in Patients With Crohn’s Disease
Author(s) -
Abhik Bhattacharya,
Daniel Travis,
Bhavana Bhagya Rao,
Mark T. Osterman,
Gary R. Lichtenstein
Publication year - 2020
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000705056.12498.00
Subject(s) - medicine , infliximab , crohn's disease , therapeutic drug monitoring , immune system , trough level , gastroenterology , cohort , inflammatory bowel disease , antibody , retrospective cohort study , drug , demographics , disease , immunology , pharmacokinetics , pharmacology , transplantation , tacrolimus , demography , sociology